Millions for BioNTech and Evotec! But drug development is costly! Is NetraMark the next takeover target?

NetraMark Holdings: Next success story – Takeover in 2026?

Artificial intelligence (AI) can save time in drug development and increase the efficiency of clinical trials. In this way, pharmaceutical and biotech companies could save billions in the future and generate revenue more quickly. To this end, NetraMark Holdings has developed the NetraAI platform, specializing in the optimization of clinical trials. NetraAI's capabilities are said to surpass traditional machine learning, generating actionable results even from small and complex clinical data sets.

NetraMark has already secured key customers and established strategic partnerships this year. The next success story came at the beginning of this week. A biopharmaceutical company will use NetraAI for a Phase 3 clinical trial of a novel psychotropic drug. NetraMark's AI will analyze multidimensional clinical data sets and deliver explainable subpopulations. For example, the response to treatment methods and placebos, as well as the occurrence of side effects, will be analyzed. The customer can incorporate the results into its strategy for approval and market access.

With this contract, NetraMark is expanding its portfolio of AI-supported projects in the fields of neuroscience, oncology, and complex pain disorders. Based on its sales success, the Company is a hot AI stock for the coming year. NetraMark's growing revenue and earnings potential, combined with its industry success, position it as a strong candidate for acquisition.

https://youtu.be/Rg_Zn7lctTk?si=u3RaIV0-fB63M2Q-

Evotec: Million-dollar payment evaporates

There has been no takeover speculation for Evotec in recent months. The stock has been highly volatile. In 2025, it has traded as high as nearly EUR 11, but also as low as EUR 5.

Most recently, the biotech company was able to celebrate a million-dollar payment. Partner Bristol Myers Squibb transferred USD 25 million for progress in the joint neurology research project. The funds are intended to accelerate the further development of the joint pipeline for the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's. The collaboration began in 2016. Since then, several innovative programs have been established, including the EVT8683 project, which has already successfully completed Phase 1 clinical trials.

The partnership was extended by eight years in 2023. The goal is to develop disease-modifying therapies that go beyond simply treating symptoms. Evotec's Chief Scientific Officer, Dr. Cord Dohrmann, emphasized that the payment confirms the close collaboration with Bristol Myers Squibb and underscores the joint mission to create new therapeutic options for patients with neurodegenerative diseases.

Neither the share price nor analysts reacted strongly to the news. Deutsche Bank recently reaffirmed its "Hold" recommendation. Analysts do not expect any positive surprises from today's quarterly figures. Their price target for Evotec shares is EUR 6. The stock is currently trading at just over EUR 7.

BioNTech: Analysts see upside potential

Analysts have recently been much more positive about BioNTech. Following the quarterly figures, Jefferies reaffirmed its "Buy" recommendation. The German biotech leader has generated more revenue than expected. The increase in the annual forecast was also well received. Analysts see the fair value of BioNTech shares at USD 151. The vaccine specialist's shares are currently trading at around USD 103.

BioNTech generated revenue of EUR 1.52 billion in the third quarter of 2025. In the previous year, the figure was EUR 1.24 billion. Despite this growth, the bottom line was a loss of EUR 28.7 million (prior year: profit of EUR 198 million). This is because BioNTech continues to go full throttle in research and development – perhaps NetraMark's AI should be used to save costs. In any case, EUR 565 million was invested. BioNTech can easily afford this. Thanks in part to a payment from Bristol Myers Squibb, cash and cash equivalents stood at EUR 16.7 billion.

Operationally, BioNTech is focusing heavily on its oncology division, particularly on the antibody candidate Pumitamig, which is being tested in several Phase 2 and Phase 3 trials. At the same time, a variant-adapted COVID-19 vaccine for the 2025/26 season was launched in several markets.

BioNTech significantly raised its revenue forecast for 2025 as a whole to EUR 2.6 to 2.8 billion. R&D and administrative costs are expected to be slightly lower than initially anticipated for the year as a whole.

The example of BioNTech shows the sums involved in developing new drugs and how great the need for cost savings is. This opens up exciting growth opportunities for NetraMark and makes the Company a potential takeover candidate in the medium term. Evotec is simply running out of steam at the moment, with even million-dollar payments failing to give the stock any momentum. BioNTech continues to have full coffers and an exciting pipeline.